BioCardia, Inc (BCDA) - Business Payback Period

Corporate emblem and logo of BioCardia, Inc (BCDA)

The historical price chart on GURU.Markets for BioCardia, Inc. (BCDA), which has a multiple of -1.80, highlights volatility driven by funding shortages and uncertainty regarding test outcomes. BioCardia, Inc. (BCDA) is developing the innovative CardiAMP project, systematically building an evidence base for regulators. Simultaneously, the business is implementing environmental standards in biolabs, with a particular focus on research ethics and the confidentiality of medical data.

BCDA BioCardia: P/E Multiple in the range 07/04/2022 - 11/10/2026

Analytical breakdowns for BioCardia, Inc.

- stock quotes and analyst forecast:
Price Chart biocardia.com|BCDA - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization BioCardia, Inc.|BCDA - Total Company Value
- book capitalization data:
Net Asset Value per Share BioCardia|BCDA - Book Capitalization|Market Cap to Net Assets Ratio biocardia.com|BCDA - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital BioCardia, Inc.|BCDA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital BioCardia Inc|BCDA - Company Aggregate Debts|Debt to Book Value Ratio BioCardia, Inc.|BCDA - Company Long-Term Debts|Short-Term Debt Volume BioCardia|Quick Ratio biocardia.com
- business earnings and investment ratios data:
BCDA - Net Income|Expected Net Income BioCardia, Inc.|BCDA - P/E Multiple|Market Cap to Projected Earnings BioCardia Inc.|BCDA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation BioCardia, Inc.|BCDA - Operating profit EBITDA|Net earnings per share for the last 12 months BioCardia|BCDA - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months biocardia.com|BCDA - Earnings growth in current year|Net earnings per share growth forecast for next year BioCardia, Inc.
Summary company analysis:biocardia.com BCDA
Core merchandise of BioCardia Inc

For BioCardia, Inc. (BCDA), the P/E ratio compares market capitalization with actual net income. This indicator measures the cost of one dollar of earnings, identifying asset overvaluation. By analyzing the company's market P/E level, an investor determines the extent of inflated market expectations. Amid high FDA testing costs, this metric highlights the gap between current losses and future margins from catheter sales. The stability of this figure confirms the fundamental resilience of the business.

Key competitors

Price to Earnings Ratio REGN|P/E Multiple IRTC|Business Payback Period Lantheus Holdings|Price to Earnings Ratio Mineralys Therapeutics Inc MLYS|HeartFlow (HTFL) - Market Cap to Earnings|Kestra Medical Technologies - P/E Multiple|esperion.com (ESPR) - Price to Earnings Ratio|AMRN: P/E Multiple|Anteris Technologies (AVR) - P/E Multiple|Price to Earnings Ratio Tenaya|CVRX: Company Value to Net Income|P/E Multiple MIST|cardiolrx.com - Price to Earnings Multiple|P/E Multiple BEAT (HeartBeam)|Business Payback Period Tenax Therapeutics Inc. (TENX)|Adagio Medical Holdings Inc. - P/E Multiple|VTAK - P/E Multiple|ABIO (arcabio.com) - Price to Earnings Ratio|Acasti Pharma Inc. - Company Value to Net Income|AVTE (Aerovate Therapeutics, Inc.) - P/E Multiple|Verve (VERV) - Business Payback Period|Price to Earnings Ratio Windtree Therapeutics (WINT)